ESR1 and carcinoma: These results are in agreement with previous data combining MEKi and fulvestrant in other human tumor models demonstrating that MEKi can be used to sensitize ERα-positive tumors to hormonal therapy, and accordingly, propose that this strategy may have broader clinical utility in other ERα-positive carcinoma [30].